Magnesium intervention during pregnancy
| ISRCTN | ISRCTN98365455 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN98365455 |
| Secondary identifying numbers | N/A |
- Submission date
- 23/08/2010
- Registration date
- 14/09/2010
- Last edited
- 05/11/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Ragnar Rylander
Scientific
Scientific
Bjorkasvagen 21
Lerum
443 91
Sweden
| Phone | +46 (0)708 40 0101 |
|---|---|
| envhealth@biofact.se |
Study information
| Study design | Double blind interventional randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Prevention |
| Participant information sheet | Not available in web format, please use contact details below to request a patient information sheet |
| Scientific title | Acid-base balance and blood pressure during pregnancy: a double-blinded randomized controlled trial |
| Study objectives | Intervention with magnesium citrate will prevent increase in blood pressure during last part of pregnancy. Further reading: http://www.ncbi.nlm.nih.gov/pubmed/20135136. |
| Ethics approval(s) | The Gothenburg Committee, 08/03/2009, ref: 098-09 |
| Health condition(s) or problem(s) studied | Pregnancy |
| Intervention | Magnesium citrate powder (Diasporal), 12 mmol magnesium daily, taken at week 25 of pregnancy until delivery. Control group receive no supplements. Blood pressure and proteinurea are measured routinely in all pregnancies |
| Intervention type | Other |
| Primary outcome measure | Blood pressure increase during final weeks of pregnancy |
| Secondary outcome measures | Symptoms of pre-eclampsia during final weeks of pregnancy |
| Overall study start date | 01/10/2010 |
| Completion date | 01/10/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target number of participants | 60 |
| Key inclusion criteria | 1. First time pregnancies 2. Urinary calcium excretion in excess of 6 mmol around pregnancy week 20 |
| Key exclusion criteria | History of blood pressure or renal dysfunction |
| Date of first enrolment | 01/10/2010 |
| Date of final enrolment | 01/10/2012 |
Locations
Countries of recruitment
- Sweden
Study participating centre
Bjorkasvagen 21
Lerum
443 91
Sweden
443 91
Sweden
Sponsor information
Sodra Alvsaborgs Hospital (Sweden)
Hospital/treatment centre
Hospital/treatment centre
Maternity care unit
Boras
501 82
Sweden
| Phone | +46 (0)33 616 0000 |
|---|---|
| Mats.elm@vgregion.se | |
"ROR" |
https://ror.org/01qas6g18 |
Funders
Funder type
Research council
South Alvsborg Research and Development Council (Forskning och Utveckling [FoU]) (Sweden)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/12/2013 | Yes | No |
